Nitrogen Other Than As Nitro Or Nitroso Nonionically Bonded Patents (Class 514/561)
-
Patent number: 10934318Abstract: The subject invention provides methods and procedures for synthesis and/or semi-synthesis of the novel antibiotic arsinothricin (AST) and derivatives. Arsinothricin (AST), a new broad-spectrum organoarsenical antibiotic, is a non-proteinogenic analog of glutamate that effectively inhibits glutamine synthetase. The subject invention provides chemical synthesis of an intermediate in the pathway of AST synthesis, hydroxyarsinothricin (AST-OH), which can be converted to AST by enzymatic methylation catalyzed by the ArsM As(III) S-adenosylmethionine methyltransferase. The methods provide a source of the novel antibiotic that will be required for future clinical trials. The subject invention also provides AST derivatives as a new class of antibiotics.Type: GrantFiled: June 5, 2020Date of Patent: March 2, 2021Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEESInventors: Barry P. Rosen, Stanislaw F. Wnuk, Masafumi Yoshinaga, Md Abu Hasan Howlader, Sk Md Sazzad Hossain Suzol
-
Patent number: 10905670Abstract: The present disclosure is directed to acetyl-leucine or a pharmaceutically acceptable salt thereof for use in improving cognitive function, mobility, or cognitive function and mobility in a subject, for example, in an elderly subject.Type: GrantFiled: April 19, 2017Date of Patent: February 2, 2021Assignee: INTRABIO LTD.Inventors: Mallory Factor, Michael Strupp
-
Method and composition for increasing muscle protein synthesis and/or functional strength in mammals
Patent number: 10888571Abstract: A method and composition for preserving muscle mass and function by increasing muscle protein synthesis and/or decreasing muscle protein degradation in mammals is disclosed. In one embodiment, the mammals are administered a protein building composition comprising at least two of an essential amino acid, an amino acid derivative, and a nitrogenous organic acid. In a particular embodiment, the protein building composition comprises leucine, L-carnitine, and creatine. The protein building composition can decrease TNF-? and increase mTOR expression in muscle.Type: GrantFiled: December 16, 2016Date of Patent: January 12, 2021Assignee: Lonza Consumer Health Inc.Inventors: Aouatef Bellamine, Ilya Zhivkovich, Ulla Freitas -
Patent number: 10874626Abstract: Formulations, methods of manufacturing, methods of stabilizing, kits, and uses as medicament are provided, for example for the treatment of pain. The formulations can comprise gabapentin optionally combined with at least one non-opioid pain drug in an aqueous carrier. The pharmaceutical formulation can have a pH of about 2.0 to about 10.0. The at least one non-opioid pain drug can be acetaminophen. The components can be included in any amount suitable for purposes of obtaining properties desirable for an injectable infusion, for example an intravenous infusion.Type: GrantFiled: April 7, 2017Date of Patent: December 29, 2020Assignee: Nevakar Inc.Inventors: Varun Khurana, Vivek Yadav, Jack Martin Lipman, Tao Zhang, Iouri V. Ilitchev, Tushar Hingorani, Kumaresh Soppimath, Navneet Puri
-
Patent number: 10870681Abstract: The present invention provides method treating a subject suffering from a clinical condition associated with CXCR4 activity, said method comprising administering to a subject in need of such a treatment a therapeutically effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof, wherein a is 0 or 1; AA1 along with the sulfur atom that is attached thereto is 3-mercaptopropionic acid, optionally substituted cysteine, or optionally substituted homocysteine; AA2 along with the sulfur atom that is attached thereto is cysteine or homocysteine; Ar1 is an optionally substituted aryl; X1 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), or Lys(iPr); X2 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), Lys(iPr), a D-isomer thereof, or absent; X3 is Gly or absent; X4 is Phe, 2Nal, 1Nal, or absent; X5 is Gly or absent; R2 is —OR4 or —NHR5; R4 is H or alkyl; and R5 is H, alkyl, optionally substituted aryl, optionally substituted aralkyl.Type: GrantFiled: June 4, 2019Date of Patent: December 22, 2020Assignee: MAINLINE BIOSCIENCES LLCInventors: Junge Zhang, Liang Zeng Yan
-
Patent number: 10786474Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.Type: GrantFiled: March 13, 2020Date of Patent: September 29, 2020Assignee: SynAgile CorporationInventors: Adam Heller, John Spiridigliozzi
-
Patent number: 10765651Abstract: The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.Type: GrantFiled: May 15, 2019Date of Patent: September 8, 2020Assignee: SyneuRx International (Taiwan) Corp.Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
-
Patent number: 10716855Abstract: A pulse photodynamic therapy (or pulse PDT) treatment of photodamaged skin is described.Type: GrantFiled: December 5, 2014Date of Patent: July 21, 2020Assignee: GALDERMA RESEARCH & DEVELOPMENTInventors: Hans Christian Wulf, Gloria Sanclemente
-
Patent number: 10695310Abstract: Methods of treatment using D-serine to target brain cells expressing GluN3 subunit-containing triheteromeric NMDARs are disclosed. The methods include inhibiting calcium ion uptake by brain cells, treating epilepsy, and treating seizures by artificially administering D-serine.Type: GrantFiled: February 25, 2019Date of Patent: June 30, 2020Assignee: Florida State University Research Foundation, Inc.Inventor: Sanjay S. Kumar
-
Patent number: 10660887Abstract: Compositions and methods for the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present Invention Is also directed to methods tor the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.Type: GrantFiled: July 16, 2017Date of Patent: May 26, 2020Assignee: GLYTECH, LLCInventor: Daniel C. Javitt
-
Patent number: 10654794Abstract: Disclosed are a fused tricyclic ?-amino acid derivative and a medical use thereof, in particular, the present invention relates to a fused cyclic ?-amino acid derivative as shown in general formula (I), or a stereoisomer, solvate, metabolite, prodrug, pharmaceutically acceptable salt or eutectic thereof, a pharmaceutical composition containing same, and the use of a compound or the composition in the field of analgesia, wherein the definitions of each substituent in general formula (I) are the same as the definitions in the description.Type: GrantFiled: September 12, 2017Date of Patent: May 19, 2020Assignee: SICHUAN HAISO PHARMACEUTICAL CO., LTD.Inventors: Yao Li, Zongjun Shi, Bo Xu
-
Patent number: 10646435Abstract: The present invention provides pasty or liquid compositions for applications on mucous membranes of cavities easily reached by hand, having a bio-adhesive prolonged effect or release. The composition includes a polysaccharide matrix agent selected from the group constituting of lambda carrageenan and iota carrageenan. The matrix allows the in situ formation of a matrix film with a reinforced bio-adhesive capacity due to complexation reactions between the polysaccharide matrix agent and the components of the local secretions of the mucous membranes. The compositions can also include a lecithin compound as a reinforcing agent of the intrinsic bio-adhesive properties of the polysaccharide matrix agent. The composition can further include at least one of (a) a hydration medium for the polysaccharide matrix agent, (b) a lecithin co-solvent allowing the dispersion of the micellar lecithin solution in the hydration medium, (c) an additive or additives, and (d) at least one active ingredient.Type: GrantFiled: April 22, 2016Date of Patent: May 12, 2020Assignee: CARE & PHARMA PERSPECTIVES SAInventor: Laurence Paris
-
Patent number: 10596136Abstract: This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.Type: GrantFiled: June 19, 2019Date of Patent: March 24, 2020Assignee: AXCELLA HEALTH INC.Inventors: Manu Chakravarthy, William Comb, Michael Hamill, Tony Tramontin
-
Patent number: 10588882Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.Type: GrantFiled: June 10, 2019Date of Patent: March 17, 2020Assignee: SynAgile CorporationInventors: Adam Heller, John Spiridigliozzi
-
Patent number: 10583138Abstract: This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.Type: GrantFiled: May 24, 2018Date of Patent: March 10, 2020Assignee: GLYTECH, LLCInventor: Daniel C. Javitt
-
Patent number: 10485776Abstract: A medicament to be applied as an external preparation for therapeutic treatment of a local symptom of a neuropathic disease, which contains gabapentin or pregabalin in the form of an aqueous solution.Type: GrantFiled: May 23, 2018Date of Patent: November 26, 2019Assignee: KEMPHYS LTD.Inventors: Koichi Shudo, Kiyoshi Sugiyama
-
Patent number: 10426792Abstract: Compositions and supplement formulations comprise at least one of Carnitine, Taurine, or derivative forms thereof. In one aspect, the composition or a supplement formulation comprises at least one Amino Acid constituent selected from the group consisting of Carnitine, Taurine, and derivative forms thereof; and at least one Nitrate constituent. In another aspect, the composition or a supplement formulation comprises a Nitrate of a compound selected from the group consisting of Carnitine, Taurine, and derivative forms thereof, wherein the Nitrate is a salt of Nitrate or a mixed salt of Nitrate. The compositions and supplement formulations may be formulated for improving athletic performance, increasing the bioabsorption of Carnitine, Taurine, or derivative forms thereof, or for increasing the vasodilative characteristics.Type: GrantFiled: February 13, 2015Date of Patent: October 1, 2019Assignee: ThermoLife International, LLCInventors: Ronald Kramer, Alexander Nikolaidis
-
Patent number: 10420783Abstract: The present invention relates to a foodstuff comprising feather hydrolysate for use in improving performance during exercise and/or improving recovery after exercise in a dog. It also relates to a method of improving the performance in a dog during exercise and/or improving recovery after exercise, the method comprising administering to a dog a foodstuff which comprises feather hydrolysate.Type: GrantFiled: June 20, 2014Date of Patent: September 24, 2019Assignee: Mars, IncorporatedInventors: Alexandre Feugier, Delphine Clero
-
Patent number: 10363246Abstract: Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.Type: GrantFiled: March 18, 2019Date of Patent: July 30, 2019Assignee: Ovid Therapeutics Inc.Inventor: Matthew During
-
Patent number: 10351608Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.Type: GrantFiled: August 7, 2015Date of Patent: July 16, 2019Assignee: Rosalind Franklin University of Medicine and ScienceInventor: Bruce L. Riser
-
Patent number: 10328041Abstract: The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.Type: GrantFiled: January 9, 2018Date of Patent: June 25, 2019Assignee: SyneuRx International (Taiwan) Corp.Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
-
Patent number: 10328044Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.Type: GrantFiled: December 14, 2018Date of Patent: June 25, 2019Assignee: SynAgile CorporationInventor: Adam Heller
-
Patent number: 10328042Abstract: The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.Type: GrantFiled: April 3, 2018Date of Patent: June 25, 2019Assignee: SyneuRx International (Taiwan) Corp.Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
-
Patent number: 10306909Abstract: The present invention is based on the finding that free amino acids can both negatively or positively influence overall taste of free amino acid-based enteral nutritional compositions, and the amino acids can thus be categorized. A striking balance of both categories of amino acids to arrive at amino acid-based nutritional composition with improved taste, yet not compromising the (regulatory) dietary restrictions on essential amino acids and conditionally essential amino acids.Type: GrantFiled: June 30, 2015Date of Patent: June 4, 2019Assignee: N.V. NUTRICIAInventors: Jonathan Rason, Carole Springett
-
Patent number: 10307387Abstract: D-serine is used to treat a neurological disorder, such as epilepsy, that cases seizures. A composition comprising D-serine is artificially administered to a patient in an effective amount by selectively contacting a region of the patient's brain with the composition. The region of the brain selectively contacted with the composition has cells expressing GluN3 subunit-containing triheteromeric NMDARs.Type: GrantFiled: December 7, 2017Date of Patent: June 4, 2019Assignee: Florida State University Research Foundation, Inc.Inventor: Sanjay Kumar
-
Patent number: 10300033Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.Type: GrantFiled: February 2, 2018Date of Patent: May 28, 2019Assignee: SynAgile CorporationInventor: Adam Heller
-
Patent number: 10265278Abstract: The present invention provides a pharmaceutical composition for oral administration comprising a D-amino acid combined with an antioxidant selected from the group consisting of vitamin E, vitamin C, a glutathione or a precursor thereof.Type: GrantFiled: February 20, 2017Date of Patent: April 23, 2019Inventor: Daniel Javitt
-
Patent number: 10255497Abstract: The invention relates to a method and to a device for authenticating and/or identifying persons, objects, or service systems. In said method, a material, a construction, a substance, or a composition, or an image thereof, either changes itself or is actively changed, by means of a physical, chemical, or mechanical influence or feature, such that the resulting structure or feature is unforeseeable. If an image of said material, of the construction, of the substance, or the composition recorded at a later time is compared with the image stored in a storage means, the person and/or the object and/or the medium and/or service system is positively authenticated if the material, the construction, the substance, or the composition has at least partially changed between the two times in comparison with the image stored in the storage means.Type: GrantFiled: March 18, 2015Date of Patent: April 9, 2019Inventor: Friedrich Kisters
-
Patent number: 10241093Abstract: The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.Type: GrantFiled: November 28, 2011Date of Patent: March 26, 2019Assignee: The Cleveland Clinic FoundationInventors: Stanley L. Hazen, Zeneng Wang, Bruce S. Levison
-
Patent number: 10188635Abstract: Methods of treating tinnitus with gaboxadol or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of tinnitus.Type: GrantFiled: August 7, 2018Date of Patent: January 29, 2019Assignee: OVID THERAPEUTICS INC.Inventor: Matthew During
-
Patent number: 10136669Abstract: A nutritional composition is provided which has an effective prophylactic and/or improving effect for various symptoms of muscle mass decrease, decreased basal metabolism, low body temperature, suppression of obesity, suppression of visceral fat accumulation, hyperglycemia, hyperlipidemia and the like in elderly people. The nutritional composition can include n-3 fatty acid and one or more of free lysine, dipeptides containing lysine, and lysine salts, wherein the content of free lysine, dipeptides containing lysine, and/or lysine salts is 0.1 g-10.0 g per 100 kcal of the composition, and the content of the total amount of n-3 fatty acid is 0.17 g-5.00 g per 100 kcal of the composition.Type: GrantFiled: August 25, 2016Date of Patent: November 27, 2018Assignee: AJINOMOTO CO., INC.Inventors: Tomoyuki Mine, Naoki Hayashi, Itaru Kon, Kazunori Saima
-
Patent number: 10137288Abstract: This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.Type: GrantFiled: November 27, 2017Date of Patent: November 27, 2018Assignee: Pop Test Abuse Deterrent Technology, LLCInventors: Randice Lisa Altschul, Neil David Theise, Razvan Andrei Ene, Myron Rapkin, Rebecca O'Brien
-
Patent number: 10098856Abstract: A combination of dosage units for alleviating respiratory ailments and a method of alleviating respiratory ailments which uses this combination of dosage units. The dosage units comprise one or more first dosage units comprising pseudoephedrine and/or a pharmaceutically acceptable salt thereof and one or more second dosage units comprising phenylephrine and/or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 2, 2016Date of Patent: October 16, 2018Assignee: Sovereign Pharmaceuticals, LLCInventors: Suresh Dixit, Juan Carlos Menendez, Ralph Brown
-
Patent number: 10076573Abstract: Biodegradable polyphosphazene polymers containing pyrrolidone side groups, and the biomedical use of such polyphosphazene polymers are disclosed.Type: GrantFiled: November 7, 2014Date of Patent: September 18, 2018Assignee: Innovo Biopolymers, LLCInventors: Alexander Andrianov, Alexander Marin
-
Patent number: 10071083Abstract: Methods of treating tinnitus with gaboxadol or a pharmaceutically acceptable salt thereof are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of tinnitus. Methods of treating acute sensorineural hearing loss or Meniere's disease with gaboxadol or a pharmaceutically acceptable salt thereof are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of acute sensorineural hearing loss or Meniere's disease.Type: GrantFiled: January 17, 2018Date of Patent: September 11, 2018Assignee: OVID THERAPEUTICS INCInventor: Matthew During
-
Patent number: 10052296Abstract: Formulations, methods of manufacturing, methods of stabilizing, kits, and uses as medicament are provided, for example for the treatment of pain. The formulations can comprise gabapentin optionally combined with at least one non-opioid pain drug in an aqueous carrier. The pharmaceutical formulation can have a pH of about 2.0 to about 10.0. The at least one non-opioid pain drug can be acetaminophen. The components can be included in any amount suitable for purposes of obtaining properties desirable for an injectable infusion, for example an intravenous infusion.Type: GrantFiled: April 7, 2017Date of Patent: August 21, 2018Assignee: NEVAKAR INC.Inventors: Varun Khurana, Vivek Yadav, Jack Martin Lipman, Tao Zhang, Iouri V. Ilitchev, Tushar Hingorani, Kumaresh Soppimath, Navneet Puri
-
Patent number: 10022446Abstract: A pH-responsive hybrid hydrogel, namely poly(Methacrylic acid-grafted-Ethylene Glycol) P(MAA-g-EG) cross-linked with Styrene-Butadiene-Styrene (SBS) polymer and photopolymerized by visible light. The resulting polymer turned out to have better integrities, high swelling ratios, pH-responsive and biocompatible character. Also the visible-light-induced synthesis of these pH-responsive composite wherein eosin Y is used as photoinitiator and triethanolamine is used as a co-initiator is also disclosed in the invention.Type: GrantFiled: August 22, 2014Date of Patent: July 17, 2018Assignee: KOç ÜNIVERSITESIInventors: Seda Kizilel, Ozlem Cevik
-
Patent number: 10018591Abstract: A method for determining the levels of biomarkers, specifically, advanced glycation end products (AGEs) and oxidation products (Ops) in a biological sample such as a plasma ultrafiltrate, is used to determine a patient's risk and/or rate of developing diabetes related nephropathy. The preferred biomarkers to measure include N?-(1-carboxyethyl-lysine (CEL), methylglyoxyl-derived hydroimidazolone (MGHI) and N?-carboxymethyllysine (CML). Also provided herein is a method of diabetic care which includes determining a diabetic patient's risk of developing diabetes related kidney disease and adjusting the patient's treatment regimen to include in addition to glucose lowering agents, additional treatments such as medications that modify the renin-angiotensin system, or specialized diets with low levels of AGEs or oxidative products.Type: GrantFiled: June 10, 2013Date of Patent: July 10, 2018Assignee: PREVENTAGE HEALTHCARE, LLCInventor: Paul J. Beisswenger
-
Patent number: 10010703Abstract: This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.Type: GrantFiled: November 27, 2017Date of Patent: July 3, 2018Assignee: Pop Test Abuse Deterrent Technology, LLCInventors: Randice Lisa Altschul, Neil David Theise, Razvan Andrei Ene, Myron Rapkin, Rebecca O'Brien
-
Patent number: 10004710Abstract: A medicament to be applied as an external preparation for therapeutic treatment of a local symptom of a neuropathic disease, which contains gabapentin or pregabalin in the form of an aqueous solution.Type: GrantFiled: September 4, 2013Date of Patent: June 26, 2018Assignee: KEMPHYS LTD.Inventors: Koichi Shudo, Kiyoshi Sugiyama
-
Patent number: 9961932Abstract: The invention pertains to the use of a composition comprising per serving between 50-300 kcal; between 10 g and 35 g proteinaceous matter; and at least 2.5 microgram vitamin D, for the manufacture of a nutritional product for (a) the treatment or prevention of muscle mass decrease, (b) stimulation of muscle mass increase; or (d) stimulating muscle mass preservation, in obese or overweight adults of at least 40 years of age participating in a weight loss program. The inventors surprisingly found that nutritional supplementation with a low-caloric composition rich in protein, particularly whey protein and leucine, compared to an iso-caloric control supplement without protein, synergistically leads to preservation of muscle mass during a weight loss program involving a hypocaloric diet and a resistance exercise program in overweight/obese older adult.Type: GrantFiled: June 10, 2013Date of Patent: May 8, 2018Assignee: N.V. NutriciaInventors: Peter Johan Marie Weijs, Johan De Vogel, George Verlaan, Marion Jourdan
-
Patent number: 9937138Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.Type: GrantFiled: March 9, 2016Date of Patent: April 10, 2018Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
-
Patent number: 9926515Abstract: The invention is related to a contact lens care solution comprising a buffer solution, a chelating agent, a surfactant and a wetting agent, wherein the wetting agent comprises 100 parts by weight of glycerol, 0.5 to 40 parts by weight of vinylacetamide-containing polymer and 5 to 40 parts by weight of alginic acid.Type: GrantFiled: January 3, 2017Date of Patent: March 27, 2018Assignee: BENQ MATERIALS CORPORATIONInventors: Fan-Dan Jan, Bo-Ching Lin, Min-Chun Chung
-
Patent number: 9925159Abstract: D-serine is used to treat a neurological disorder, such as epilepsy, that cases seizures. A composition comprising D-serine is artificially administered to a patient in an effective amount by selectively contacting a region of the patient's brain with the composition. The region of the brain selectively contacted with the composition has cells expressing GluN3 subunit-containing triheteromeric NMDARs.Type: GrantFiled: May 15, 2015Date of Patent: March 27, 2018Assignee: The Florida State University Research Foundation, Inc.Inventor: Sanjay Kumar
-
Patent number: 9913808Abstract: The present invention relates to an injectable pharmaceutical formulation for the alleviation or reduction of joint irritation or for the reduction of worsening of existing joint inflammation, formulated for intra-articular injection comprising an active polyol ingredient, which polyol active ingredient is xylitol. Use of the intra-articular injectable formulations for the treatment of joint diseases or conditions including arthritis is described.Type: GrantFiled: June 15, 2011Date of Patent: March 13, 2018Inventor: David Segal
-
Patent number: 9901561Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.Type: GrantFiled: March 2, 2017Date of Patent: February 27, 2018Assignee: SynAgile CorporationInventors: Adam Heller, Ephraim Heller, Karl Göran Westerberg, John Spiridigliozzi
-
Patent number: 9878138Abstract: This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.Type: GrantFiled: May 4, 2015Date of Patent: January 30, 2018Assignee: Pop Test Abuse Deterrent Technology LLCInventors: Randice Lisa Altschul, Neil David Theise, Razvan Andrei Ene, Myron Rapkin, Rebecca O'Brien
-
Patent number: 9877942Abstract: The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I): compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, suicidal ideation and/or behavior, obsessive compulsive disorder or Alzheimer's disease). Also provided herein are methods for preparing the co-crystals.Type: GrantFiled: February 13, 2017Date of Patent: January 30, 2018Assignee: SyneuRx International (Taiwan) Corp.Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
-
Patent number: 9878139Abstract: This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.Type: GrantFiled: April 21, 2017Date of Patent: January 30, 2018Assignee: Pop Test Abuse Deterrent Technology, LLCInventors: Randice Lisa Altschul, Neil David Theise, Razvan Andrei Ene, Myron Rapkin, Rebecca O'Brien
-
Patent number: 9833403Abstract: The invention described herein is related to the preparation and usage of nanoemulsions and nanoparticles which containing biological active ingredients including cosmetic, medical and pharmaceutical active ingredients to pass skin barriers and promote cell growth with evident clinical effects. Also, the present invention contains a cosmetic formulation that can be used for skin rejuvenation, wrinkle removal, scar treatment and wounds healing.Type: GrantFiled: December 31, 2013Date of Patent: December 5, 2017Inventors: Huiwen Liu, Boke Zhang